MENU
+Compare
XLO
Stock ticker: NASDAQ
AS OF
Mar 11 closing price
Price
$0.79
Change
-$0.05 (-5.95%)
Capitalization
39.68M

XLO Xilio Therapeutics Forecast, Technical & Fundamental Analysis

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments... Show more

XLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for XLO with price predictions
Mar 10, 2025

XLO sees its Stochastic Oscillator climbs out of oversold territory

On March 07, 2025, the Stochastic Oscillator for XLO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 46 instances where the indicator left the oversold zone. In of the 46 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XLO advanced for three days, in of 139 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for XLO moved out of overbought territory on February 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator moved out of overbought territory. In of the 13 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on February 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XLO as a result. In of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XLO turned negative on February 27, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at .

XLO moved below its 50-day moving average on February 27, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for XLO crossed bearishly below the 50-day moving average on March 04, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XLO broke above its upper Bollinger Band on February 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.255) is normal, around the industry mean (11.729). P/E Ratio (0.000) is within average values for comparable stocks, (64.632). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (6.684) is also within normal values, averaging (235.265).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly better than average price growth. XLO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
XLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

XLO is expected to report earnings to fall 173.91% to 16 cents per share on May 07

Xilio Therapeutics XLO Stock Earnings Reports
Q1'25
Est.
$0.16
Q4'24
Beat
by $0.04
Q3'24
Beat
by $0.03
Q2'24
Missed
by $0.01
Q1'24
Missed
by $0.51
The last earnings report on February 26 showed earnings per share of -21 cents, beating the estimate of -25 cents. With 1.24M shares outstanding, the current market capitalization sits at 39.68M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
828 Winter Street
Phone
+1 857 524-2466
Employees
73
Web
https://www.xiliotx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KRO7.610.28
+3.82%
Kronos Worldwide
SPXC133.610.85
+0.64%
SPX Technologies
CNI95.46-2.69
-2.74%
Canadian National Railway
GHG2.45-0.07
-2.78%
GreenTree Hospitality Group Ltd
VCIG0.61-0.07
-10.35%
VCI Global Limited

XLO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, XLO has been loosely correlated with APTO. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if XLO jumps, then APTO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XLO
1D Price
Change %
XLO100%
-6.99%
APTO - XLO
33%
Loosely correlated
+5.68%
CRMD - XLO
31%
Poorly correlated
+0.28%
AXON - XLO
31%
Poorly correlated
-2.08%
VKTX - XLO
30%
Poorly correlated
-3.92%
AVTX - XLO
28%
Poorly correlated
-9.66%
More